MedTrace Logo

Mitoquines in COPD

NCT04449419 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2020-06-26

No results posted yet for this study

Summary

The most important pathogenic factor of Chronic Obstructive Pulmonary Disease (COPD) in the Western world is chronic exposure to tobacco smoke, which induces oxidative stress not only in the respiratory system, but in all the body. Mitoquines are circulating hormones directly or indirectly produced by dysfunctional mitochondria, whose function is to protect the body of the consequences of oxidative stress. The objective of this project is to study the modifications that are produced in the serum mitoquines from patients with COPD of varying severity and to assess their potential applications in the clinic.

Conditions

  • COPD Exacerbation

Interventions

OTHER

There is not intervention.

There is not intervention

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Hospital Universitario Marqués de Valdecilla

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2020-11-01
Completion
2021-06-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04449419 on ClinicalTrials.gov